WallStreetZenWallStreetZen

NASDAQ: CLLS
Cellectis Sa Stock Forecast, Predictions & Price Target

Analyst price target for CLLS

Based on 1 analyst offering 12 month price targets for Cellectis Sa.
Min Forecast
$6.00+135.29%
Avg Forecast
$6.00+135.29%
Max Forecast
$6.00+135.29%

Should I buy or sell CLLS stock?

Based on 1 analyst offering ratings for Cellectis Sa.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CLLS stock forecasts and price targets.

CLLS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-01

1 of 1

Forecast return on equity

Is CLLS forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
36%

Forecast return on assets

Is CLLS forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

CLLS revenue forecast

What is CLLS's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$24.6M+0.57%
Avg 2 year Forecast
$31.6M+29.25%
Avg 3 year Forecast
$102.7M+320.54%
CLLS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CLLS revenue growth forecast

How is CLLS forecast to perform vs Biotechnology companies and vs the US market?
Company
55.61%
Industry
38.03%
Market
10.06%
CLLS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CLLS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CLLS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
CLLS$2.55$6.00+135.29%Buy
RGLS$2.13$7.25+240.38%Buy
ZURA$3.31$16.00+383.38%Buy
MDWD$15.77$28.00+77.55%Buy
RZLT$3.43$9.75+184.26%Strong Buy

Cellectis Sa Stock Forecast FAQ

Is Cellectis Sa Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: CLLS) stock is to Buy CLLS stock.

Out of 1 analyst, 0 (0%) are recommending CLLS as a Strong Buy, 1 (100%) are recommending CLLS as a Buy, 0 (0%) are recommending CLLS as a Hold, 0 (0%) are recommending CLLS as a Sell, and 0 (0%) are recommending CLLS as a Strong Sell.

If you're new to stock investing, here's how to buy Cellectis Sa stock.

What is CLLS's revenue growth forecast for 2024-2026?

(NASDAQ: CLLS) Cellectis Sa's forecast annual revenue growth rate of 55.61% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.03%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.06%.

Cellectis Sa's revenue in 2024 is $24,410,000.On average, 2 Wall Street analysts forecast CLLS's revenue for 2024 to be $1,364,581,504, with the lowest CLLS revenue forecast at $472,462,028, and the highest CLLS revenue forecast at $2,256,700,981. On average, 2 Wall Street analysts forecast CLLS's revenue for 2025 to be $1,753,667,880, with the lowest CLLS revenue forecast at $694,797,100, and the highest CLLS revenue forecast at $2,812,538,661.

In 2026, CLLS is forecast to generate $5,705,951,704 in revenue, with the lowest revenue forecast at $5,108,704,117 and the highest revenue forecast at $6,303,199,291.

What is CLLS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CLLS) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is CLLS's Price Target?

According to 1 Wall Street analyst that have issued a 1 year CLLS price target, the average CLLS price target is $6.00, with the highest CLLS stock price forecast at $6.00 and the lowest CLLS stock price forecast at $6.00.

The Wall Street analyst predicted that Cellectis Sa's share price could reach $6.00 by Nov 1, 2024. The average Cellectis Sa stock price prediction forecasts a potential upside of 135.29% from the current CLLS share price of $2.55.

What is CLLS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CLLS) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.